logo
  

Health Care REIT To Buy HealthLease Properties REIT's Outstanding Units

Health Care REIT, Inc. (HCN) has agreed to acquire the outstanding units of HealthLease Properties Real Estate Investment Trust (HLP_UN.TO) for C$14.20 per unit on a fully diluted basis in an all-cash transaction worth around $950 million, including debt assumption. The HealthLease portfolio consists of 53 high-quality seniors housing, post-acute care and long-term care communities that are managed by well-respected operators under long-term triple-net lease deals. The portfolio's purchase price represents a 7.0% initial cash yield. HCN expects the acquisition of the portfolio to be accretive to HCN's FFOPS and FADPS by around $0.04 in year one.

Further, HCN has teamed up with Mainstreet Property Group, the external management company of HealthLease. All existing deals between HealthLease and Mainstreet would be terminated at closing and HCN would not absorb any employees from either company. Mainstreet is the largest developer of seniors housing and post-acute facilities in the U.S.

Also, HCN inked an agreement with Mainstreet to provide mezzanine financing at attractive mid-teen interest rates and receive purchase rights at HCN's option for an additional 45 Next Generation development projects managed by well-respected operators under long-term triple-net lease agreements. The Future Pipeline represents a $1.0 billion acquisition pipeline at a 7.7% initial cash yield, which is anticipated to be meaningfully accretive. The Future Pipeline is anticipated to close in tranches upon completion of construction beginning in 2016 through the first quarter of 2017.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT